Is Abbott Laboratories (ABT) the Top Pick in the Medical Devices Industry?

Wednesday, July 29, 2020 10:56 AM | InvestorsObserver Analysts

Abbott Laboratories (ABT) is near the top in its industry group according to InvestorsObserver. ABT gets an overall rating of 66. That means it scores higher than 66 percent of stocks. Abbott Laboratories gets a 94 rank in the Medical Devices industry. Medical Devices is number 52 out of 148 industries.

Overall Score - 66
ABT has an Overall Score of 66. Find out what this means to you and get the rest of the rankings on ABT!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 66 would rank higher than 66 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Abbott Laboratories Stock Today?

Abbott Laboratories (ABT) stock is trading at $102.31 as of 10:41 AM on Wednesday, Jul 29, a rise of $2.43, or 2.43% from the previous closing price of $99.88. The stock has traded between $100.09 and $102.47 so far today. Volume today is less active than usual. So far 1,096,443 shares have traded compared to average volume of 5,254,284 shares.

To see InvestorsObserver's Sentiment Score for Abbott Laboratories click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Where Does G1 Therapeutics Inc (GTHX) Stock Fall in the Biotechnology Field?

Should You Buy Arca Biopharma Inc (ABIO) in Biotechnology Industry?

Should BioCryst Pharmaceuticals, Inc. (BCRX) be in Your Portfolio?

Does Editas Medicine Inc (EDIT) Have What it Takes to be in Your Portfolio?

Related Companies